- Home
- HPK vs ORIC Comparison
HPK vs ORIC Comparison
Compare HPK & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HPK | ORIC |
|---|---|---|
| Founded | 2019 | 2014 |
| Country | United States | United States |
| Employees | 50 | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 955.3M | 861.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | HPK | ORIC |
|---|---|---|
| Price | $7.85 | $8.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 13 |
| Target Price | $12.00 | ★ $19.73 |
| AVG Volume (30 Days) | 775.9K | ★ 1.7M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.30% | N/A |
| EPS Growth | N/A | ★ 19.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.73 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.85 | $7.23 |
| 52 Week High | $11.80 | $14.93 |
Technical Indicators
Market Signals| Indicator | HPK | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 56.85 | 49.46 |
| Support Level | $6.62 | $7.60 |
| Resistance Level | $8.19 | $9.13 |
| Average True Range (ATR) | 0.53 | 0.58 |
| MACD | 0.02 | 0.07 |
| Stochastic Oscillator | 71.35 | 58.38 |
Price Performance
Historical ComparisonAbout HPK HighPeak Energy Inc.
HighPeak Energy Inc is an independent crude oil and natural gas exploration and production company that explores for, develops and produces crude oil, NGL, and natural gas prominently in Howard County of the Midland Basin. The company operates in a single segment, which is crude oil and natural gas development, exploration, and production in the U.S. The majority of the company's revenue is derived from the Crude oil sales.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.